title: Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin.
abstract: Melatonin is an indolamine mostly produced in the pineal gland, soluble in water, and highly lipophilic, which allows it to readily cross the blood-brain barrier. Melatonin possesses antioxidant properties and its long-term administration in rodents has not been found to cause noteworthy side effects. In the present work, we found that millimolar concentrations of this indolamine reduced cell growth of C6 glioma cells by 70% after 72 hours of treatment, inhibiting cell progression from G(1) to S phase of the cell cycle. Intraperitoneal administration of 15 mg/kg body weight of melatonin to rats previously injected in the flank with C6 glioma cells reduces tumor growth by 50% 2 weeks after the implant. Inhibition of cell growth does not depend on melatonin membrane receptor activation whereas it seemingly relates to the reduction of intracellular basal free radical levels by 30%. Increase of basal redox state of the cells and constitutive activation of tyrosine kinase receptor [receptor tyrosine kinase (RTK)] pathways, including the extracellular signal-regulated kinase 1/2 (ERK1/2) and the Akt and protein kinase C (PKC) signaling pathways, contribute to the progression of the gliomas leading to the constitutive activation of the redox-dependent survival transcription factor nuclear factor kappaB (NF-kappaB). The antioxidant effect of melatonin in C6 cells is associated to inhibition of NF-kappaB and Akt, but not of ERK1/2. The antiproliferative effect of the indolamine on these cells is partially abolished when coincubated with the PKC activator 12-O-tetradecanoylphorbol-13-acetate, thus indicating that the ability of melatonin to change cellular redox state may be inactivating the pathway RTK/PKC/Akt/NF-kappaB.
authors.affiliation: Departamento de Morfología y Biología Celular, Facultad de Medicina de la Universidad de Oviedo, Calle Julian Claveria, 33006 Oviedo, Spain.
authors.forename: Vanesa
authors.initials: V
authors.lastname: Martín
authors.forename: Federico
authors.initials: F
authors.lastname: Herrera
authors.forename: Pilar
authors.initials: P
authors.lastname: Carrera-Gonzalez
authors.forename: Guillermo
authors.initials: G
authors.lastname: García-Santos
authors.forename: Isaac
authors.initials: I
authors.lastname: Antolín
authors.forename: Jezabel
authors.initials: J
authors.lastname: Rodriguez-Blanco
authors.forename: Carmen
authors.initials: C
authors.lastname: Rodriguez
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000502:physiology*; D001932:Brain Neoplasms / Q000473:pathology*; D002453:Cell Cycle; D049109:Cell Proliferation / Q000187:drug effects*; D005609:Free Radicals; D005910:Glioma / Q000473:pathology*; D008550:Melatonin / Q000502:physiology*; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D016328:NF-kappa B / Q000096:biosynthesis; D010084:Oxidation-Reduction; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology; D051381:Rats; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
chemical_list: D000975:Antioxidants; D005609:Free Radicals; D016328:NF-kappa B; D051057:Proto-Oncogene Proteins c-akt; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D008550:Melatonin